ERBB2 and neoplasm: Other described causes of trastuzumab resistance are altered or alternative HER2 downstream signaling pathways, changed immune-related processes, changed metabolic processes, tumor cell plasticity, altered angiogenesis or intratumoral heterogeneity [63–69].